Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
São Paulo med. j
; São Paulo med. j;140(3): 372-377, May-June 2022. tab, graf
Article
em En
| LILACS
| ID: biblio-1377393
Biblioteca responsável:
BR1.1
ABSTRACT
ABSTRACT BACKGROUND:
Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey.OBJECTIVE:
To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN ANDSETTING:
Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey.METHODS:
357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups.RESULTS:
Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea.CONCLUSION:
In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
COVID-19
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
São Paulo med. j
Assunto da revista:
Cirurgia Geral
/
Cincia
/
Ginecologia
/
MEDICINA
/
Medicina Interna
/
Obstetr¡cia
/
Pediatria
/
Sa£de Mental
/
Sa£de P£blica
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Turquia
País de publicação:
Brasil